255 related articles for article (PubMed ID: 33025947)
1. Tapinarof to treat psoriasis.
Rodríguez Baisi K; Tollefson M
Drugs Today (Barc); 2020 Aug; 56(8):515-530. PubMed ID: 33025947
[TBL] [Abstract][Full Text] [Related]
2. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.
Bissonnette R; Stein Gold L; Rubenstein DS; Tallman AM; Armstrong A
J Am Acad Dermatol; 2021 Apr; 84(4):1059-1067. PubMed ID: 33157177
[TBL] [Abstract][Full Text] [Related]
3. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.
Armstrong AW; McConaha JL
J Manag Care Spec Pharm; 2023 Dec; 29(12-a Suppl):S2-S14. PubMed ID: 38014659
[TBL] [Abstract][Full Text] [Related]
4. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.
Smith SH; Jayawickreme C; Rickard DJ; Nicodeme E; Bui T; Simmons C; Coquery CM; Neil J; Pryor WM; Mayhew D; Rajpal DK; Creech K; Furst S; Lee J; Wu D; Rastinejad F; Willson TM; Viviani F; Morris DC; Moore JT; Cote-Sierra J
J Invest Dermatol; 2017 Oct; 137(10):2110-2119. PubMed ID: 28595996
[TBL] [Abstract][Full Text] [Related]
5. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.
Armstrong AW; McConaha JL
J Manag Care Spec Pharm; 2023 Dec; 29(12-a Suppl):S1-S13. PubMed ID: 38051146
[TBL] [Abstract][Full Text] [Related]
6. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.
Robbins K; Bissonnette R; Maeda-Chubachi T; Ye L; Peppers J; Gallagher K; Kraus JE
J Am Acad Dermatol; 2019 Mar; 80(3):714-721. PubMed ID: 30612986
[TBL] [Abstract][Full Text] [Related]
7. Tapinarof cream for the topical treatment of plaque psoriasis in adults.
Prieto K; Duong JQ; Feldman SR
Expert Rev Clin Immunol; 2024 Apr; 20(4):327-337. PubMed ID: 38117596
[TBL] [Abstract][Full Text] [Related]
8. Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis.
Bobonich M; Gorelick J; Aldredge L; Bruno MJ; DiRuggiero D; Martin G; Tallman AM; Gold LS
J Drugs Dermatol; 2023 Aug; 22(8):779-784. PubMed ID: 37556512
[TBL] [Abstract][Full Text] [Related]
9. A Review of Topical Tapinarof for the Treatment of Plaque Psoriasis.
Grossmann MC; Pixley JN; Feldman SR
Ann Pharmacother; 2024 Jan; 58(1):76-85. PubMed ID: 37076998
[TBL] [Abstract][Full Text] [Related]
10. Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research.
Bissonnette R; Saint-Cyr Proulx E; Jack C; Maari C
J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):1168-1174. PubMed ID: 36708084
[TBL] [Abstract][Full Text] [Related]
11. A Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults.
Kalabalik-Hoganson J; Nogid A; Frey K
J Drugs Dermatol; 2023 Aug; 22(8):761-765. PubMed ID: 37556516
[TBL] [Abstract][Full Text] [Related]
12. VTAMA
Gupta AK; Ravi SP; Vincent K; Abramovits W
Skinmed; 2022; 20(4):298-300. PubMed ID: 35976021
[TBL] [Abstract][Full Text] [Related]
13. Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.
Jett JE; McLaughlin M; Lee MS; Parish LC; DuBois J; Raoof TJ; Tabolt G; Wilson T; Somerville MC; DellaMaestra W; Piscitelli SC
Am J Clin Dermatol; 2022 Jan; 23(1):83-91. PubMed ID: 34713415
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R
N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448
[TBL] [Abstract][Full Text] [Related]
15. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
Stein Gold L; Bhatia N; Tallman AM; Rubenstein DS
J Am Acad Dermatol; 2021 Mar; 84(3):624-631. PubMed ID: 32446832
[TBL] [Abstract][Full Text] [Related]
16. Tapinarof Cream 1%: First Approval.
Keam SJ
Drugs; 2022 Jul; 82(11):1221-1228. PubMed ID: 35939180
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis.
Eichenfield LF; Silverberg JI; Hebert AA; Chovatiya R; Brown PM; McHale KA; Rubenstein DS; Tallman AM
J Drugs Dermatol; 2024 Feb; 23(2):23-28. PubMed ID: 38306128
[TBL] [Abstract][Full Text] [Related]
18. Tapinarof and the future of topical treatments in plaque psoriasis.
Assaf J; Sarkis J; Tomb R
J Am Acad Dermatol; 2021 Jun; 84(6):e283-e284. PubMed ID: 33508393
[No Abstract] [Full Text] [Related]
19. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial.
Strober B; Stein Gold L; Bissonnette R; Armstrong AW; Kircik L; Tyring SK; Piscitelli SC; Brown PM; Rubenstein DS; Tallman AM; Lebwohl MG
J Am Acad Dermatol; 2022 Oct; 87(4):800-806. PubMed ID: 35772599
[TBL] [Abstract][Full Text] [Related]
20. The opposite effect of tapinarof between IMQ and IL-23 induced psoriasis mouse models.
Zhu X; Han R; Tian X; Hochgerner M; Li H; Wang J; Xia J
Exp Dermatol; 2024 Jan; 33(1):e14862. PubMed ID: 37350230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
